Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time with AstraZeneca overseeing global marketing strategy for Rhinocort and Rhinocort Aqua. He was most recently Senior VP, Head of Gastrointestinal and Internal Medicine Business Unit at Shire.
Arikayce is in Phase 3 clinical development for the treatment of nontuberculous mycobacteria (NTM) lung disease. In June 2016, the company announced that it had withdrawn an MAA for Arkikayce that it had submitted to the EU in 2014, saying that it would resubmit the application once it had data from an ongoing Phase 3 trial.
Insmed President and CEO Will Lewis Commented, “Roger is a seasoned executive with a proven track record of success in bringing therapies to market. I am very pleased he will be joining Insmed as we look forward to the commercialization of Arikayce and additional products. Roger has extensive experience of ensuring optimal performance of marketed products and his global marketing expertise will be invaluable to our future as we prepare to become a commercial-stage pharmaceutical company.”
Adsett said, “I am thrilled to have the opportunity to join Insmed at such a promising time in the company’s history. I am looking forward to working with the talented team here to execute on the company’s global strategy, and to further its goal of meeting the unmet therapeutic needs of patients with NTM lung disease and other rare disorders.”
Read the Insmed press release.
